Takeda China offers cash, medical supplies to help fight pandemic
The COVID-19 outbreak remains a major concern worldwide. As a value-based and R&D-driven global biopharmaceutical company, Takeda is committed to protecting the health of Chinese patients. Ever since the outbreak was reported, Takeda has acted quickly to provide support and help combat the pandemic.
To date, the company has donated nearly 6 million yuan (US$850,000) in cash and medical supplies to help combat the COVID-19 outbreak in China.
Sean Shan, president of Takeda China, said: "Our thoughts are with those who are affected by this terrible pandemic. We appreciate that medical staff, health professionals and all sectors of society are working together to help those at the forefront of the fight against this outbreak. Being part of the community, Takeda is prepared to play its role. As the pandemic evolves, we are closely monitoring the situation, and are committed to offering our support and assistance to better protect the health of patients in China."
Recently, Takeda China announced an additional donation of medical products valued at over 3.4 million yuan through the Chinese Red Cross Foundation. These products will be used in the ICUs of designated hospitals to support the treatment of patients infected with COVID-19 in Hubei Province and other regions seriously affected by the outbreak.
Shortly after the COVID-19 outbreak was reported, Takeda China was among the first multinational pharmaceutical companies that announced donations of 1 million yuan in cash and over 1 million yuan of protective medical supplies through the CRCF to support pandemic control in Wuhan, Hubei Province.
Teams across Takeda mobilized global resources and medical supplies from Japan, the US and Germany, including masks and protective medical suits which were delivered to key designated hospitals in Wuhan, to support medical staff working on the front line.
Upon request by the Cancer Foundation of China, Takeda China also donated 1,500 medical jumpsuits to assist medical teams providing help in Hubei from cancer hospitals across China.
Managing and preventing the spread of the pandemic remains the biggest challenge around the world. On March 4, Takeda announced that it would share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients.
SARS-CoV-2 is the virus that causes COVID-19. Hyperimmune globulins are plasma-derived therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19.